Apelin-13通过抑制转化生长因子β1信号改善LPS诱导的内皮-间质转化和急性肺损伤后肺纤维化
该研究探讨apelin-13对LPS诱导的急性肺损伤(ALI)内皮-间质转化(EndMT)及ALI后肺纤维化的作用及机制。研究者检测脓毒症相关ARDS患者血清apelin-13水平,并采用LPS诱导的小鼠肺纤维化模型和LPS刺激的人肺微血管内皮细胞损伤模型,分别给予apelin-13腹腔注射和体外孵育。结果显示,脓毒症相关ARDS患者循环apelin-13水平较健康对照显著升高;LPS诱导EndMT进展和肺纤维化(表现为CD31表达下降、α-平滑肌肌动蛋白表达升高和胶原沉积),并刺激转化生长因子β1产生及激活Smad信号通路,而apelin-13处理显著减轻上述变化。作者认为apelin-13可能成为脓毒症相关ARDS的新型生物标志物,并通过抑制转化生长因子β1信号改善LPS诱导的EndMT和ALI后肺纤维化。
要点
- 脓毒症相关ARDS患者循环apelin-13水平较健康对照显著升高,提示其可能作为该人群的新型生物标志物。
- LPS诱导小鼠肺纤维化模型中出现EndMT进展和肺纤维化,表现为CD31表达下降、α-平滑肌肌动蛋白表达升高和胶原沉积。
- LPS刺激转化生长因子β1产生并激活Smad信号通路,apelin-13腹腔注射处理可显著减轻上述改变。
- 体外LPS刺激的人肺微血管内皮细胞经apelin-13孵育后,EndMT相关变化同样被显著减轻。
- 作者认为apelin-13通过抑制转化生长因子β1信号改善LPS诱导的EndMT和ALI后肺纤维化。
适用人群与场景
- 脓毒症相关ARDS患者(检测血清apelin-13水平)
- LPS诱导肺纤维化小鼠模型
- LPS刺激的人肺微血管内皮细胞损伤模型
处置流程与药物剂量
- 小鼠经腹腔注射给予apelin-13处理。
- 人肺微血管内皮细胞在体外与apelin-13共同孵育。
研究设计与关键结果
- 脓毒症相关ARDS患者循环apelin-13水平较健康对照显著升高。
- LPS诱导EndMT进展和肺纤维化,表现为CD31表达下降、α-平滑肌肌动蛋白表达升高和胶原沉积。
- LPS刺激转化生长因子β1产生并激活Smad信号通路,apelin-13处理显著减轻这些变化。
- 作者认为apelin-13可能成为脓毒症相关ARDS的新型生物标志物。
证据类型、等级与局限
- 证据类型:基础研究(小鼠模型和体外细胞实验)结合患者血清标志物检测。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为apelin-13可能成为脓毒症相关ARDS的新型生物标志物,并可能通过抑制转化生长因子β1信号改善LPS诱导的EndMT和ALI后肺纤维化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The pathophysiology of acute respiratory distress syndrome (ARDS) involves cytokine storms, alveolar-capillary barrier destruction, and fibrotic progression. Pulmonary interstitial fibrosis is an important factor affecting the prognosis of ARDS patients. Endothelial-to-mesenchymal transition (EndMT) plays an important role in the development of fibrotic diseases, and the occurrence of EndMT has been observed in experimental models of LPS-induced acute lung injury (ALI). Apelin is an endogenous active polypeptide that plays an important role in maintaining endothelial cell homeostasis and inhibiting fibrotic progression in various diseases. However, whether apelin attenuates EndMT in ALI and post-ALI pulmonary fibrosis remains unclear. We analyzed the serum levels of apelin-13 in patients with sepsis-associated ARDS to examine its possible clinical value. A murine model of LPS-induced pulmonary fibrosis and an LPS-challenged endothelial cell injury model were used to analyze the protective effect and underlying mechanism of apelin-13. Mice were treated with apelin-13 by i.p. injection, and human pulmonary microvascular endothelial cells were incubated with apelin-13 in vitro . We found that the circulating apelin-13 levels were significantly elevated in sepsis-associated ARDS patients compared with healthy controls. Our study also confirmed that LPS induced EndMT progression and pulmonary fibrosis, which were characterized by decreased CD31 expression and increased α-smooth muscle actin expression and collagen deposition. LPS also stimulated the production of transforming growth factor β1 and activated the Smad signaling pathway. However, apelin-13 treatment significantly attenuated these changes. Our findings suggest that apelin-13 may be a novel biomarker in patients with sepsis-associated ARDS. These results demonstrate that apelin-13 ameliorates LPS-induced EndMT and post-ALI pulmonary fibrosis by suppressing transforming growth factor β1 signaling.
参考来源
- Liu H, Shi Q, Tang L, et al. APELIN-13 AMELIORATES LPS-INDUCED ENDOTHELIAL-TO-MESENCHYMAL TRANSITION AND POST-ACUTE LUNG INJURY PULMONARY FIBROSIS BY SUPPRESSING TRANSFORMING GROWTH FACTOR-Β1 SIGNALING. Shock. 2022. PMID: 36377383. doi:10.1097/SHK.0000000000002046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。